Mingxia Jiang

Xiamen University

H指数:19

被引数:1,977

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Aspirin-Induced Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Osteochondral Regeneration by Reprogramming Macrophages

阿司匹林诱导的间充质干细胞来源的细胞外囊泡通过重编程巨噬细胞促进骨软骨再生

Biomaterials

IF12.9

2026-03-230

PRE

Opportunities and Challenges of Biomaterials in Brain Disease

脑疾病中生物材料的机会与挑战

Advanced Healthcare Materials

IF9.6

2025-06-050

PRE

Microfluidic colorimetric biosensor for rapid and sensitive detection of Shewanella oneidensis MR-1

SENSORS AND ACTUATORS B-CHEMICAL

IF7.7

2025-02-011

PRE

Metabolism of cancer cells and immune cells in the initiation, progression, and metastasis of cancer

癌症细胞和免疫细胞在癌症起始、进展和转移过程中的代谢

THERANOSTICS

IF13.3

2025-01-017

PRE

Recent advances in poly(amino acids), polypeptides, and their derivatives in drug delivery

NANOSCALE

IF5.1

2025-01-010

PRE

Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study

BMC CANCER

IF3.4

2024-10-181

OAAI

Synergistically enhanced cancer immunotherapy by combining protamine-based nanovaccine with PD-L1 gene silence nanoparticle (vol 242, 125223, 2023)

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

IF8.5

2024-10-010

PRE

Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis

BMC CANCER

IF3.4

2024-07-221

OAAI

Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement

聚焦理想的靶抗原和抗体-药物结合物的耐药性: 竞争进步的策略

DRUG RESISTANCE UPDATES

IF21.7

2024-07-015

PRE

Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer

CANCER RESEARCH

IF16.6

2024-05-020

PRE

SERS combined with the difference in bacterial extracellular electron transfer ability to distinguish Shewanella

SERS结合细菌胞外电子传递能力差异区分希瓦氏菌

SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

IF4.6

2023-12-011

PRE

Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis

阿帕替尼联合剂量密集紫杉醇和卡铂新辅助治疗局部晚期三阴性乳腺癌的疗效和安全性: 倾向匹配分析的前瞻性队列研究

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2023-09-073

OAAI

Autogenous iron-based peroxidase-like nanozyme from paper mill sludge for ascorbic acid detection

MATERIALS TODAY COMMUNICATIONS

IF4.5

2023-08-013

PRE

Synergistically enhanced cancer immunotherapy by combining protamine-based nanovaccine with PD-L1 gene silence nanoparticle

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

IF8.5

2023-07-015

PRE

The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2023-06-147

PRE

Leveraging Nanodrug Delivery System for Simultaneously Targeting Tumor Cells and M2 Tumor-Associated Macrophages for Efficient Colon Cancer Therapy

利用纳米药物递送系统同时靶向肿瘤细胞和M2肿瘤相关巨噬细胞进行有效的结肠癌治疗

ACS APPLIED MATERIALS & INTERFACES

IF8.2

2022-11-037

PRE

Buffet-style Cu(II) for enhance disulfiram-based cancer therapy

JOURNAL OF COLLOID AND INTERFACE SCIENCE

IF9.7

2022-10-0125

PRE

Co-loaded lapatinib/PAB by ferritin nanoparticles eliminated ECM-detached cluster cells via modulating EGFR in triple-negative breast cancer

CELL DEATH & DISEASE

IF9.6

2022-06-2037

OAAI

Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis (vol 520, pg 143, 2021)

CANCER LETTERS

IF10.1

2022-01-010

PRE

Selective thermotherapy of tumor by self-regulating photothermal conversion system

JOURNAL OF COLLOID AND INTERFACE SCIENCE

IF9.7

2022-01-0114

PRE

Mingxia Jiang

个人简介

教育背景

工作经历

荣誉奖项

研究方向